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TO THE EDITOR
The formation of a competent barrier at
the interface to the terrestrial environ-
ment is a fundamental function of the
skin. Acute or sustained insult to the
stratum corneum results in perturbation
of the barrier integrity and generates an
array of positive and negative down-
stream alarm signals that initiate both
homeostatic and proinflammatory
responses (Nickoloff and Naidu, 1994;
Elias, 2005). The compromised barrier
integrity therefore might not be merely
an end point but also trigger the release
of cytokines of critical importance to
the initiation of allergic skin inflamma-
tion and the manifestation of common
disease entities such as atopic dermati-
tis (AD) (Elias et al., 1999; Elias and
Steinhoff, 2008).
Of particular interest in that context
is thymic stromal lymphopoietin (TSLP),
an IL-7-like cytokine preferentially exp-
ressed by the epithelial cells at the
interfaces such as the skin, airways, and
gut (Liu et al., 2007). The critical role of
TSLP in the initiation of allergic inflam-
mation is well established and although
there has been progress in unveiling
the factors triggering TSLP expression,
the underlying mechanisms are not
fully understood (Li et al., 2006; Liu
2006, 2007; Lee et al., 2008). Cultured
skin explants and primary human
epithelial cells were shown to release
TSLP upon inflammatory, bacterial, and
Table 1. Noninvasive bioengineering assessment of the barrier-function parameters at baseline and following
irritant application or tape stripping in vivo
A. 96-h repeated open application test
Parameter Baseline SLS-treated field Baseline control field + 96 h SLS-treated field + 96h control field
TEWL, gm2 h1 5.49±0.38 5.45±0.32 33.64±2.56a***, b*** 5.64±0.32
Chroma a*-, AU 5.82±0.5 5.76±0.5 12.05±1.34a***, b*** 5.64±0.61
Skin pH, AU 5.09±0.16 4.97±0.13 6.11±0.19a**, b** 5.12±0.15
Capacitance, AU 37.3±1.78 37.36±1.76 19.22±2.10a***, b*** 36.63±1.76
B. Single 24-h application of 2% SLS
Parameter Baseline SLS-treated field Baseline control field + 24 h SLS-treated field + 24h control field
TEWL, gm2 h1 6.21±0.18 5.51±0.36 42.16±7.76a**, b** 5.41±0.30
Chroma a*-, AU 6.76±0.24 6.69±0.31 12.23±1.54a*, b** 5.93±0.25
Skin pH, AU 4.96±0.35 5.26±0.19 7.15±0.08a*, b** 4.92±0.12
Capacitance, AU 51.84±2.28 50.49±2.77 32.20±5.31a**, b* 49.29±2.95
C. Tape stripping
Parameter Baseline TS field +100 Strips TS field Control field
TEWL, gm2 h1 4.83±0.66 61.57±1.92a***, b*** 4.82±0.65
Chroma a*-, AU 3.66±1.21 10.87±1.84a**, b** 3.80±0.99
Abbreviations: AU, arbitrary units; SLS, sodium lauryl sulfate; TEWL, transepidermal water loss; TS, tape stripping.
All data are presented as mean±SEM and differences are considered significant when Po0.05.
aValues compared with baseline; bvalues compared with control field; *Po0.05; **Po0.01; ***Po0.001.
Abbreviations: AD, atopic dermatitis; SLS, sodium lauryl sulfate; TEWL, transepidermal water loss
TS, tape stripping; ROAT, repeated open application test
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viral stimuli or trauma (Allakhverdi
et al., 2007; Bogiatzi et al., 2007). In
human skin, TSLP is expressed by
keratinocytes in lesional skin of AD
patients, but not in nickel-induced
allergic contact dermatitis and systemic
lupus erythematosus (Soumelis et al.,
2002). Compromised barrier function is
characteristic for AD, therefore we
aimed at investigating the role of tape
stripping (TS) and irritant damage to the
stratum corneum for the expression of
human TSLP in vivo.
For the purpose, we analyzed TSLP
expression in skin biopsies obtained
from healthy, adult, nonatopic volun-
teers following: (1) repeated open
application (ROAT) of 2% sodium
lauryl sulfate (SLS) for 96 hours (n¼ 8);
(2) single 24-hour application of 2%
SLS under occlusion (n¼4); (3) sequen-
tial TS until removal of the stratum
corneum (n¼4). A biopsy from adja-
cent nontreated field served as control
(normal skin).
Visual scoring and bioengineering
assessment of the barrier function of the
test and control (nontreated) fields were
performed as follows: (1) ROAT base-
line and every 24 hours up to 96 hours;
(2) patch test baseline and 2 hours after
removal of the test chamber; (3) TS
baseline and upon complete removal
of the stratum corneum. Erythema was
measured using Chromameter CR200
(Minolta, Osaka, Japan) and expressed
in the L*a*b* system. Transepidermal
water loss (TEWL) was measured with
the open chamber system (Tewameter
TM300), skin pH was monitored using
the skin pH meter PH905 and skin
hydration was assessed by measuring
capacitance (Corneometer CM825), all
devices from Courage and Khazaka
Electronics (Cologne, Germany). For
each parameter, three consecutive
measurements per field were performed
by the same observer under controlled
ambient conditions (room temperature
21±2 1C; relative humidity 35–45%).
At the end of the observation period
(96 hours for ROAT, 24 hours for the
patch test and 48 hours for TS),
5-mm punch biopsies from the test
and control fields were taken for
immunohistochemistry and quantifica-
tion of TSLP mRNA by real-time
quantitative PCR. The study was
conducted according to the Declaration
of Helsinki principles. The protocol was
approved by the Ethics Committee of
the University of Lu¨beck and all
participants gave written consent
beforehand.
*
* *
*
*
*
Figure 1. TSLP expression in human skin after tape stripping and SLS application in vivo. (a, b) Hematoxylin–
eosin staining of SLS-treated field: (a) 96-hour repeated application; (b) 24-hour patch test. (c–e) Cryosections
from SLS-treated and tape-stripped skin stained with sheep or rat anti-human TSLP mAb (R&D Systems
and kind gift from Rene de Waal Malefyt, respectively). TSLP expression is restricted to the epidermis
and detectable in the suprabasal cell layers (arrows), while the basal layer (asterisk) remains negative:
(c) 96-hour open test; (d) 24-hour occlusion test; (e) 48 hours after tape stripping. (f–h) No detectable
TSLP immunoreactivity in frozen sections from adjacent field (normal skin) of the same volunteers.
(i) TSLP expression by crypt epithelial cells of human tonsil: positive control. (j) Adjacent section
of human tonsil: isotype control. Scale bar¼15 mm.
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Tape stripping and SLS application
resulted in moderately severe inflam-
matory reaction reflected by significant
increase in the visual score of the test
fields compared with baseline and
the nontreated field. The compromised
barrier integrity was evidenced by the
significant increase in TEWL, chroma-
metry a*-value, skin pH, and significant
decrease in capacitance of the test
fields compared with baseline, while
the barrier-function parameters of
the control field remained unchanged
(Table 1). Histopathology changes com-
patible with irritant dermatitis were
present on hematoxylin-eosin-stained
sections from SLS-treated skin (Figure
1a and b) and absent in the control
samples.
TSLP-specific focal immunoreactiv-
ity was present in seven out of eight
samples obtained from the test field on
which barrier damage was induced by
repetitive SLS application (Figure 1c), in
one out of four samples obtained from
the SLS patch test field (Figure 1d) and
in four out of four samples obtained
from the TS field (Figure 1e), whereas
the samples from the control field
remained consistently negative (Figure
1f–h). TSLP was expressed by keratino-
cytes in the suprabasal cell layers,
mainly the spinous and granular layers,
and absent in the basal layer and these
findings were consistent across the
samples (Figure 1c–e). These observa-
tions are in agreement with previously
published data suggesting that TSLP
expression is a feature of keratinocytes
undergoing terminal differentiation
(Soumelis et al., 2002; Liu 2007).
Similarly to earlier reports, we found
dissociation in TSLP expression at the
protein and mRNA levels (Bogiatzi
et al., 2007) as TSLP mRNA levels in
TS samples were comparable with
control skin (data not shown).
The pathways leading to human
TSLP expression upon tape stripping
or irritant damage to the epidermis
in vivo remain to be determined.
Previously, human TSLP was shown
to be induced under the synergistic
effects of proinflammatory and Th2
cytokines (Bogiatzi et al., 2007).
Recent evidence for TSLP release
by Notch-deficient keratinocytes in
engineered mice showing skin
barrier defects and eczema-like pheno-
type (Demehri et al., 2008, 2009)
suggests a link between barrier inte-
grity and TSLP. In agreement with
these observations, the results of our
study make reasonable to speculate that
alterations in the permeability barrier
function play a role for human TSLP
expression. Injury to the stratum cor-
neum, barrier integrity, and inflamma-
tory signaling are intricately interrelated
and mechanistic separation of the
downstream events in in vivo human
skin system is difficult as perturbation
in one function ultimately impacts the
other.
In summary, our findings provide
evidence that injury to the stratum
corneum by tape stripping and irritant
application induces the expression
of human TSLP in the epidermis. The
pattern of immunoreactivity is consis-
tent independently of the mechanism
to induce barrier damage. To the best
of our knowledge in vivo inducible
upregulation of TSLP in human skin
has not been previously reported.
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